Automated insulin delivery technology. Photo: Supplied / Ben Wheeler
Professor Ben Wheeler. Photo: Supplied / Ben Wheeler
Every day our bodies automatically makes hundreds of decisions that we are completely unaware of. But for those suffering from diabetes, it's a different story.
PHARMAC has expanded funding for gold standard technology that will drastically reduce the number of decisions those with type 1 diabetes have to make.
Type 1 diabetes affects up to 25,000 people in Aotearoa, with loss of up to 20 years life expectancy reported, especially in those diagnosed at a young age, and of Māori/Pacific ethnicity.
Ben Wheeler is a professor at the University of Otago's Department of Women and Children's Health.
He has been awarded $1.4 million from the Health Research Council to evaluate a model of delivery that will provide better access to the tech for all who need it.
